Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (44 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 30 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painpregabalinchronicinabilitygabapentin
  Phrases that lowered it: effectpatients undergoingelectivepostprofile
• Drug's FAERS reports with a death: 8.2% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: supportive care (lowers risk) · Design
• Drug's FAERS reports marked serious: 75.0% (lowers risk) · Drug's FDA history
• Blinding: single (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 15 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 22024 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 25 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery NCT01811251 · started 2012 · scored riskier than 65% of active trials completed
• Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Spine Fixation Surgery NCT04342065 · started 2019 · scored riskier than 6% of active trials completed
• Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae NCT03031340 · started 2012 · scored riskier than 25% of active trials terminated
• Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy NCT00735124 · started 2008 · scored riskier than 38% of active trials terminated
• Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE). NCT03158376 · started 2015 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.